Company: PETVW
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001493152-25-011967
Chunk: 33

Company: PetVivo Holdings, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---
 -  
     - 
  
    Outstanding,
    June 30, 2025 
     14,875,956  
    $2.37  
     1.83  
    $2.37 

Stock-based compensation expense for warrants was $74,024 and $42,395 for the three months ended June 30, 2025, and 2024, respectively. At June 30, 2025, there was $869,054 of future unrecognized warrant expense, to be expensed quarterly over the remaining life of the warrants, over the
next 26 months.

NOTE
14 – SEGMENT REPORTING

The Company manages the business activities on a
consolidated basis and operates in one reportable segment. The Company’s reportable segment is an emerging biomedical device company
focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for animals. The segment
is animal health products. As the Company has one reportable segment, sales and marketing, research and development, including clinical
trial expenses and general and administrative expenses are equal to consolidated results. Financial results for the Company’s reportable
segment have been prepared using a management approach, which is consistent with the basis and manner in which financial information
is evaluated by the Company’s Chief Operating Decision Maker (“CODM”) in allocating resources and in assessing performance.
The Company’s CODM is the Chief Financial Officer. The measurement of segment profit or loss that the CODM uses to evaluate the
performance of the Company’s segment is net income attributable to animal health. The CODM reviews financial budgets and actual
results as assess performance and allocate resources, and makes strategic decisions related to headcount and other expenditures on a consolidated
basis. The CODM considers the impact of the significant segment expenses in the table below on operating income (loss) when deciding
where and when to make expenditures.

 SCHEDULE
OF SEGMENT INFORMATION

    June
    30, 2025  
    June
    30, 2024 

    For
    the Three Months Ended 

    June
    30, 2025  
    June
    30, 2024 
  
    NET REVENUE 
    $297,500  
    $123,751 
  
    Cost of Sales 
     110,774  
     12,994 
  
    Gross Profit 
     186,726  
     110